Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LAPATINIB DITOSYLATE Cause Interstitial lung disease? 9 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Interstitial lung disease have been filed in association with LAPATINIB DITOSYLATE (Lapatinib). This represents 0.2% of all adverse event reports for LAPATINIB DITOSYLATE.

9
Reports of Interstitial lung disease with LAPATINIB DITOSYLATE
0.2%
of all LAPATINIB DITOSYLATE reports
1
Deaths
4
Hospitalizations

How Dangerous Is Interstitial lung disease From LAPATINIB DITOSYLATE?

Of the 9 reports, 1 (11.1%) resulted in death, 4 (44.4%) required hospitalization, and 2 (22.2%) were considered life-threatening.

Is Interstitial lung disease Listed in the Official Label?

Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for LAPATINIB DITOSYLATE.

What Other Side Effects Does LAPATINIB DITOSYLATE Cause?

Diarrhoea (893) Death (665) Nausea (317) Fatigue (301) Vomiting (259) Rash (249) Drug ineffective (183) Malignant neoplasm progression (183) Off label use (141) Disease progression (137)

What Other Drugs Cause Interstitial lung disease?

METHOTREXATE (3,049) RITUXIMAB (2,458) PEMBROLIZUMAB (2,113) PREDNISONE (1,850) CYCLOPHOSPHAMIDE (1,725) NIVOLUMAB (1,538) AMIODARONE (1,421) DOXORUBICIN (1,352) ETANERCEPT (1,267) ADALIMUMAB (1,250)

Which LAPATINIB DITOSYLATE Alternatives Have Lower Interstitial lung disease Risk?

LAPATINIB DITOSYLATE vs LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN LAPATINIB DITOSYLATE vs LARONIDASE LAPATINIB DITOSYLATE vs LAROTRECTINIB LAPATINIB DITOSYLATE vs LASILIX LAPATINIB DITOSYLATE vs LASIX

Related Pages

LAPATINIB DITOSYLATE Full Profile All Interstitial lung disease Reports All Drugs Causing Interstitial lung disease LAPATINIB DITOSYLATE Demographics